Attila Varkonyi

Szeged University Technology Transfer Company (SZTE TTC) bridges the gap between academic research and real-world applications, facilitating collaboration with partners to bring university discoveries to both domestic and international audiences. It seeks and initiates international interdisciplinary collaborations and assists innovations in entering the market. By establishing foreign trade channels, they facilitate participation in international co-innovation projects. These projects leverage university expertise alongside global partners to address sustainable development challenges, effectively turning university-developed technologies into global benefits.

👉𝐖𝐡𝐨 𝐰𝐞 𝐚𝐫𝐞 Cytocast: a research-focused and data-driven techbio company, providing a cell simulation platform, that can revolutionize how we treat patients starting from drug discovery and development (Cytocast™ Simulated Cell) to selecting the best treatment option for patients (Cytocast™ Digital Twin). 𝐂𝐲𝐭𝐨𝐜𝐚𝐬𝐭 𝐯𝐢𝐬𝐢𝐨𝐧 In the future, therapies tailored for each patient will be designed by a computer model of a human cell, harnessing patient-specific whole-cell simulation platform. 𝐂𝐲𝐭𝐨𝐜𝐚𝐬𝐭 𝐦𝐢𝐬𝐬𝐢𝐨𝐧 Committed to developing cutting-edge, patient-specific medical technology solutions that benefit a broad range of clients in the healthcare industry. 𝐂𝐲𝐭𝐨𝐜𝐚𝐬𝐭 𝐭𝐞𝐚𝐦 Dedicated team with unique and diverse skillset: computational biologists, bioinformaticians, developers and researchers shaping the future of medicine. 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 Cytocast is proud to have a strong group of investors committed to revolutionizing drug discovery and the personalized healthcare industry through in silico cell simulation. Our investors include: Creative Accelerator, Bonitás Asset Management, KDT Holding, Fastventures, Futurmed, Zoiros Ventures 🤝We are actively seeking investors who share our vision and are interested in supporting our mission and growth. 📬𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐢𝐟: • ...you want to learn more about how Cytocasts technology can benefit your organization • ...youre a visionary pharma company, research institution, or healthcare professional eager to advance drug development, lets collaborate and redefine possibilities together! • ...you are interested in collaborating with us as a Pilot Study Partner, to validate the effectiveness of our CytocastTM Simulated Cell technology • ...youre interested in featuring a story about Cytocast’s mission or conducting an interview with our team members, feel free to reach out. We are open to collaboration and eager to share our insights and expertise

APPERCELL is delivering a novel in vitro platform that allows the automatic, simultaneous and long-term recording of the activity of neural networks growing on a large number of MEA (multi-electrode array) plates. The company also building an innovative, cloud-based solution to analyze the vast amount of data recorded, and to discover new information with the help of machine learning.

Ambrichor provides access to biological samples for the development and regulatory validation of blood-based cancer tests. Ambrichor collects plasma samples from a high risk, asymptomatic cohort of individuals and cancer patients. Our first indication is lung cancer, in which our region has the highest incidence worldwide. The sample collection fulfils the most rigorous pre-analytical requirements of cell free nucleic acid, exosome or epitope analysis. It also fulfils the regulatory, quality control and documentation requirements of clinical validation for registration studies submitted to Notified Bodies or US Food and Drug Administration.

Neunos Ltd is combining the latest advances of neuroscience with cutting-edge microelectronic approaches in order to provide a therapeutic solution based on oscillatory interference with ongoing neuronal network activity. We develop a minimally-invasive, implantable seizure suppression system, which automatically detects the onset of epileptic seizures and promptly terminates them by transcranial electrical stimulation before fatal accidents evolve. Treating epileptic seizures is our main focus, however we are continuously looking for new opportunities and alternative perspectives to deepen our knowledge in neuropsychiatric disorders, and find new non-pharmaceutical therapeutic approaches. Join us in making an impact by changing lives today.

Neunos Ltd is combining the latest advances of neuroscience with cutting-edge microelectronic approaches in order to provide a therapeutic solution based on oscillatory interference with ongoing neuronal network activity. We develop a minimally-invasive, implantable seizure suppression system, which automatically detects the onset of epileptic seizures and promptly terminates them by transcranial electrical stimulation before fatal accidents evolve. Treating epileptic seizures is our main focus, however we are continuously looking for new opportunities and alternative perspectives to deepen our knowledge in neuropsychiatric disorders, and find new non-pharmaceutical therapeutic approaches. Join us in making an impact by changing lives today.

Banzai Cloud is a platform for pipeline developers designed to simplify the creation, deployment, and scalability of contemporary cloud applications. Our platform makes use of an automation and execution engine that offers deployment automation adapted for different applications. We enable enterprises and corporateclients to ensure the security of their infrastructure.

Automatic scorekeeping for steel darts.

Cryptowerk is the leading data integrity company, using blockchain to authenticate digital assets. With Cryptowerk, organizations can detect and deter data tampering, verifying that assets are pristine and can be trusted. With patented technology that unlocks the power of blockchain, Cryptowerk enables enterprise-wide and cross-organizational data verification.

Renovos is a new regenerative medicine company capitalising on the decades of world-class stem cell and orthopaedic research from the University of Southampton. Renovos is developing next-generation regenerative medicine solutions, based on a synthetic nanoclay gel technology platform, Renovite. Renovos offers a complementary range of products and services to address the needs of researchers and clinicians, developing solutions for tissue healing that is quicker, safer and more cost-effective.

Avatao is a hands-on secure coding learning platform used by developers, security champions, pentesters, security analysts, and DevOps teams around the world to improve their IT security knowledge, and to speed up secure product development. The Avatao platform offers more than 600 real-life tutorials and challenges in the most popular programming languages, covering the most crucial security topics, from secure DevOps via API security to cryptography. Whether you need to teach your developers the fundamentals in a security awareness training, provide them a continuous training based on career tracks or build a security champions program, Avatao is the right tool for you.

Meet Carv 2: A coach for every skier, on every terrain. Better skiers have more fun, but getting better doesn’t happen by chance. That’s why we built Carv 2. Tiny, yet powerful. Our wearable sensors clip to any boot, capturing your every turn to provide personalized tips, so you can take on harder terrain and look cool doing it.

SigmaDrugs is a Budapest based biotech start-up company founded in 2015. We are dedicated to developing novel applications of Sigma-1 receptor agonists for the treatment of chronic fibrotic diseases including end-stage renal failure, idiopathic pulmonary fibrosis as well as fibrosis in the eye. Preclinical studies have been completed, the patent has been accepted in the US, Europe, Israel, China, and Japan. In parallel, SigmaDrugs Ltd is also developing a patented preservation solution for organ transplantation which promotes protection of the graft, thus alleviating donor organ shortage and facilitating improved transplantation outcomes.

Make X-ray imaging safer and more powerful! Kinepict Health Ltd. was founded in 2015 and rose as a result of 20+ years of research. So far our team has completed several clinical studies validating our patented Digital Variance Angiography (DVA) technology, published peer-reviewed papers in leading radiology journals to prove the benefits of DVA. This technology is integrated into the Kinepict Medical Imaging Tool (KMIT) which is a CE marked and FDA cleared class IIa medical device software and fully complies with ISO 13485 standard. KMIT has provided safer and faster interventions for more than 10,000 patients so far in our reference site network.

Szeged University Technology Transfer Company (SZTE TTC) bridges the gap between academic research and real-world applications, facilitating collaboration with partners to bring university discoveries to both domestic and international audiences. It seeks and initiates international interdisciplinary collaborations and assists innovations in entering the market. By establishing foreign trade channels, they facilitate participation in international co-innovation projects. These projects leverage university expertise alongside global partners to address sustainable development challenges, effectively turning university-developed technologies into global benefits.

👉𝐖𝐡𝐨 𝐰𝐞 𝐚𝐫𝐞 Cytocast: a research-focused and data-driven techbio company, providing a cell simulation platform, that can revolutionize how we treat patients starting from drug discovery and development (Cytocast™ Simulated Cell) to selecting the best treatment option for patients (Cytocast™ Digital Twin). 𝐂𝐲𝐭𝐨𝐜𝐚𝐬𝐭 𝐯𝐢𝐬𝐢𝐨𝐧 In the future, therapies tailored for each patient will be designed by a computer model of a human cell, harnessing patient-specific whole-cell simulation platform. 𝐂𝐲𝐭𝐨𝐜𝐚𝐬𝐭 𝐦𝐢𝐬𝐬𝐢𝐨𝐧 Committed to developing cutting-edge, patient-specific medical technology solutions that benefit a broad range of clients in the healthcare industry. 𝐂𝐲𝐭𝐨𝐜𝐚𝐬𝐭 𝐭𝐞𝐚𝐦 Dedicated team with unique and diverse skillset: computational biologists, bioinformaticians, developers and researchers shaping the future of medicine. 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 Cytocast is proud to have a strong group of investors committed to revolutionizing drug discovery and the personalized healthcare industry through in silico cell simulation. Our investors include: Creative Accelerator, Bonitás Asset Management, KDT Holding, Fastventures, Futurmed, Zoiros Ventures 🤝We are actively seeking investors who share our vision and are interested in supporting our mission and growth. 📬𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐢𝐟: • ...you want to learn more about how Cytocasts technology can benefit your organization • ...youre a visionary pharma company, research institution, or healthcare professional eager to advance drug development, lets collaborate and redefine possibilities together! • ...you are interested in collaborating with us as a Pilot Study Partner, to validate the effectiveness of our CytocastTM Simulated Cell technology • ...youre interested in featuring a story about Cytocast’s mission or conducting an interview with our team members, feel free to reach out. We are open to collaboration and eager to share our insights and expertise

APPERCELL is delivering a novel in vitro platform that allows the automatic, simultaneous and long-term recording of the activity of neural networks growing on a large number of MEA (multi-electrode array) plates. The company also building an innovative, cloud-based solution to analyze the vast amount of data recorded, and to discover new information with the help of machine learning.

Ambrichor provides access to biological samples for the development and regulatory validation of blood-based cancer tests. Ambrichor collects plasma samples from a high risk, asymptomatic cohort of individuals and cancer patients. Our first indication is lung cancer, in which our region has the highest incidence worldwide. The sample collection fulfils the most rigorous pre-analytical requirements of cell free nucleic acid, exosome or epitope analysis. It also fulfils the regulatory, quality control and documentation requirements of clinical validation for registration studies submitted to Notified Bodies or US Food and Drug Administration.